TY - JOUR T1 - Changes in Reproductive Rate of SARS-CoV-2 Due to Non-pharmaceutical Interventions in 1,417 U.S. Counties JF - medRxiv DO - 10.1101/2020.05.31.20118687 SP - 2020.05.31.20118687 AU - Jie Ying Wu AU - Benjamin D. Killeen AU - Philipp Nikutta AU - Mareike Thies AU - Anna Zapaishchykova AU - Shreya Chakraborty AU - Mathias Unberath Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/01/2020.05.31.20118687.abstract N2 - In response to the rapid spread of the novel coronavirus, SARS-CoV-2, the U.S. has largely delegated implementation of non-pharmaceutical interventions (NPIs) to local governments on the state and county level. This staggered implementation combined with the heterogeneity of the U.S. complicates quantification the effect of NPIs on the reproductive rate of SARS-CoV-2.We describe a data-driven approach to quantify the effect of NPIs that relies on county-level similarities to specialize a Bayesian hierarchical inference model based on observed fatalities. Using this approach, we estimate change in reproductive rate, Rt, due to implementation of NPIs in 1,417 U.S. counties.We estimate that as of May 28th, 2020 1,177 out of the considered 1,417 U.S. counties have reduced the reproductive rate of SARS-CoV-2 to below 1.0. The estimated effect of any individual NPI, however, is different across counties. Stay-at-home orders were estimated as the only effective NPI in metropolitan and urban counties, while advisory NPIs were estimated to be effective in more rural counties. The expected level of infection predicted by the model ranges from 0 to 28.7% and is far from herd immunity even in counties with advanced spread.Our results suggest that county characteristics are pertinent to re-opening decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was undertaken by the authors pro bono.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was necessary for this work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the manuscript is available from public sources. https://github.com/JieYingWu/COVID-19_US_County-level_Summaries https://coronavirus.jhu.edu ER -